Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

4.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.6K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

2.6K
Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
2.6K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

5.3K
The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.3K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

3.6K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
3.6K
Abnormal Proliferation02:23

Abnormal Proliferation

5.1K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A Cooperative Release of Mitochondrial DNA From Platelets and Neutrophils Drives an Interferon Signature in Systemic Sclerosis.

Arthritis & rheumatology (Hoboken, N.J.)·2025
Same author

Association of BMI with radiographic incidence and progression of distal interphalangeal joint osteoarthritis in rheumatoid arthritis patients.

Scientific reports·2025
Same author

Meteorosensitivity of patients with rheumatic musculoskeletal diseases.

PloS one·2025
Same author

[Long-standing myalgia and hypouricemia in a young woman : Case report and review of the literature].

Zeitschrift fur Rheumatologie·2025
Same author

Oral Glucocorticoids for Skin Fibrosis in Early Diffuse Systemic Sclerosis: A Target Trial Emulation Study From the European Scleroderma Trials and Research Group Database.

Arthritis care & research·2024
Same author

Plasma mtDNA as a possible contributor to and biomarker of inflammation in rheumatoid arthritis.

Arthritis research & therapy·2024
Same journal

Plasma proteome differences between giant cell arteritis and polymyalgia rheumatica: a pilot study.

Arthritis research & therapy·2026
Same journal

Elucidating the mechanism of taurine in alleviating osteoarthritis progression based on bioinformatics, machine learning algorithm, and experimental validation.

Arthritis research & therapy·2026
Same journal

Discovery of biomarkers for primary Sj ögren's syndrome based on multi-omics data, construction of diagnostic models, and clinical correlation analysis.

Arthritis research & therapy·2026
Same journal

Identification of distinct subgroups in Chinese patients with Behçet's syndrome via cluster analysis of immune cells and clinical features.

Arthritis research & therapy·2026
Same journal

Artemisinin increases susceptibility to ferroptosis of fibroblast-like synoviocytes in rheumatoid arthritis.

Arthritis research & therapy·2026
Same journal

Tripartite motif containing 21 autoimmunity primes CD8<sup>+</sup> cell-mediated lung inflammation: an in vivo model of interstitial lung disease pathogenesis.

Arthritis research & therapy·2026
See all related articles

Related Experiment Video

Updated: Jan 11, 2026

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
13:22

Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

Published on: October 23, 2019

8.2K

More about masitinib.

Ulrich A Walker

    Arthritis Research & Therapy
    |August 12, 2009
    PubMed
    Summary
    This summary is machine-generated.

    Masitinib, an oral tyrosine kinase inhibitor, showed efficacy in rheumatoid arthritis patients, achieving American College of Rheumatology (ACR) responses. However, high withdrawal rates due to adverse events warrant further investigation into long-term safety.

    More Related Videos

    Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
    06:51

    Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

    Published on: July 21, 2018

    18.5K
    Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
    09:38

    Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

    Published on: August 11, 2017

    9.2K

    Related Experiment Videos

    Last Updated: Jan 11, 2026

    Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
    13:22

    Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays

    Published on: October 23, 2019

    8.2K
    Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
    06:51

    Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer

    Published on: July 21, 2018

    18.5K
    Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
    09:38

    Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

    Published on: August 11, 2017

    9.2K

    Area of Science:

    • Rheumatology
    • Pharmacology
    • Immunology

    Background:

    • A phase II trial evaluated masitinib, an oral tyrosine kinase inhibitor, for rheumatoid arthritis treatment.
    • The study involved 43 patients, assessing dose-escalation and efficacy.
    • No placebo group was utilized in this trial design.

    Discussion:

    • Masitinib demonstrated clinical activity, with 54% achieving ACR20, 26% ACR50, and 8% ACR70 responses.
    • A significant proportion of patients (37%) discontinued treatment before 12 weeks due to adverse events.
    • This study provides initial evidence for tyrosine kinase inhibition in rheumatoid arthritis.

    Key Insights:

    • Masitinib exhibits potential therapeutic benefits in rheumatoid arthritis.
    • Adverse events represent a significant challenge, impacting treatment adherence.
    • Further research is needed to identify specific tyrosine kinase targets and assess long-term safety.

    Outlook:

    • Future studies should pinpoint the key tyrosine kinase(s) driving rheumatoid arthritis.
    • Investigate potential long-term toxicities, including gonadal, teratogenic, and cardiotoxic effects.
    • Optimize masitinib dosing and safety profiles for rheumatoid arthritis management.